/Investor DB

FCA Venture Partners — 2022 Investments

4 investments dated 2022 · listed companies and verified rows first · show all

Azra Aiazra-ai.comJan 2022

Azra AI provides a closed-loop patient management platform that tracks patients from clinical detection through completed care using structured workflows with defined ownership and measurable accountability.

AI & Machine LearningDigital HealthEnterprise SoftwareHealthtechMedical DevicesFranklin, US

John Marshall(Chief Executive Officer)inBrook Blackmore(Chief Strategy and Product Officer)inRyan King(Chief Technology Officer)in

BoardBraden Lambros(Director)John Burch(Director)inAbinav Sankar(Director)

Co-investorsConnexa CapitalLIP Ventures BoutiqueSJF VenturesSopris Venture Capital

Carallelcarallel.comDec 2022 · $8.2M

HealthtechChicago, US

Shara Cohen(President and CEO)inMARIA PERRIN(Director)

BoardJohn Banta(Director)inTodd Johnson(Director)Emma Cartmell(Director)in

Co-investors412 Venture FundCartmell VenturesHatteras Venture PartnersLOUD CapitalBlueCross BlueShield Venture PartnersCREATE HEALTH VENTURES+1 more

OhMDohmd.comin𝕏Feb 2022

OhMD provides a voice AI system for medical practices that automatically answers routine patient phone calls—such as scheduling, appointment reminders, prescription refills, and general questions—and resolves them by voice or text.

AI & Machine LearningDigital HealthHealthtech

Ethan Bechtel(Founder)in

Co-investorsDudley FundVermont Center for Emerging Technologies (VCET)

Virgovirgosvs.comin𝕏Aug 2022

Virgo develops foundation models and AI software for endoscopy, enabling gastroenterologists to analyze colonoscopy videos for diagnostic scoring, patient outcome prediction, and clinical trial acceleration.

AI & Machine LearningFintechHealthtechMedical DevicesSan Francisco, US

Matt Schwartz(Founder)Paul Thomas Croft(Executive Officer)Jonathan Frost(Executive Officer)

Co-investorsCeltic House Asia PartnersCerity Partners VenturesHalf Court VenturesTechstarsWaterline VenturesTom Williams

Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.